Abstract
Background: Molecularly targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have prolonged survival of pts with activating EGFR mutations in non-small cell lung cancer (NSCLC). Afatinib is an ErbB family blocker that demonstrated clinical benefit in pts with NSCLC with common and uncommon activating EGFR mutations. The activity of afatinib in other tumor types with EGFR mutations is less well known. National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Arm EAY131-A evaluated afatinib in tumors beyond lung cancer that harbored EGFR activating alterations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
